Acurx Pharmaceuticals, Inc. ACXP 深 沪
已收盘 10-09 16:00:00 美东时间
1.27
+0.020
+1.60%
华盛通- 最 高1.28
- 今 开1.24
- 成交量 4.02万股
- 最 低 1.24
- 昨 收 1.25
- 总市值 694.85万
- 52周最高 7.5392
- 市盈率 静 --
- 换手率 0.74%
- 52周最低 1.23
- 委 比 -3.40%
- 总股本 547.13万
- 历史最高 176.40
- 量 比 0.52
- 振 幅 3.20%
- 历史最低 1.23
- 每 手 1
- 风险率 1.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
Acurx Pharmaceuticals Says First Patient Enrolled In New PATHFINDER Clinical Trial In Patients With Multiply Recurrent C. Difficile Infection
PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in the broader patient population for the treatment of acute CDI, has potential to ...
09-29 20:07
Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call
Acurx Pharmaceuticals (NASDAQ:ACXP) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis...
09-18 20:03
Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.37) by 43.24 percent. This is a 71.96 percent increase over losses of $(1.89) per share from the same period last year.
08-14 19:02
Acurx Pharmaceuticals Announces Intent For Further Discussion With FDA Regarding Ibezapolstat's Phase 3 Clinical Program, Scope Of Its Planned NDA
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the successful outcome of a Type C Meeting conducted with FDA on July 13, 2026 to discuss ibezapolstat's Phase 3 cli...
08-03 20:08
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibi...
04-29 20:00
Acurx Pharmaceuticals Announces $7.1M Registered Direct Offering Of 825,085 Shares At $3.03/Share
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
04-16 20:10
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Immutep (NASDAQ:IMMP) shares rose 135.4% to $0.74 during Wednesday's p...
04-15 20:05
Acurx Pharma Granted Korean Patent For DNA Polymerase IIIC Inhibitors Including Compositions‑Of‑Matter, Methods Of Use, And Pharmaceutical Compositions
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today
03-30 19:17
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y., March 30, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of sm...
03-30 19:01
